We are going for this long opportunity. More details in our private...
Hi traders, My thoughts on Pfizer to bottom out. My level of interest is based on my common values for Elliott wave count based on a few assumptions. If it plans out, we will look for a long. For now, expect a breakdown with this rising channel as the LH and LL overlap, bearish in nature. All the best, S.SAri
Holding strong support 29 above trendline breakout Possible 31/33/36 can test soon
My thoughts showing how an extended bear move could result in the downward test of a previous bear trend line I do expect however that one of the green trend lines will hodl so I have put price labels on each of those. It is more likely to continue up than to make this horrid move. Imagine it going down to $3!
PFE weekly data is conveying significant accumulation at the current price range. Net positive volume has been increasing on a daily basis for the past few days -- in anticipation of the company's incoming price growth, long term. The stock is currently sitting at 78.6 FIB level -- a discounted level where buyers converge. Expect some significant bounce from...
MRNA has been on fire since the earnings beat 4 weeks ago and has added 60% to its market cap in the past three months. It compares well with NVAX which as a prior penny stock has more volatility and upside potential. In general vaccine stocks are performing well as COVID RSV and influenza vaccines are active in research are Viral Hepatitis vaccine...
NVAX powered off its earnings and a news catalyst and is overdue now for a correction. While in an ascending channel NVAX is now at the bottom of the channel perhaps due to the general market moves this week. From here it can move up in the channel or breakdown and fall into a significant correction from the uptrend since May 10th. I am bullish on NVAX and...
Hello everyone, today I want to discuss Pfizer's stock which experienced a 58% correction from its peak price and is currently trading around $26. I believe this stock has a lot of potential for both scalpers and long-term investors. With a dividend yield of 6.65% at this price, it's an attractive investment option. Additionally, the earnings report due this week...
Triple top on M15 Hittin Daily and H4 trend Stop loss above 32 There is a pattern on M30
This video is part of a video series where I backtest a specific asset using the TradingView Replay function, and perform a top-down analysis using ICT's Concepts in order to frame ONE high-probability setup. I choose a random point of time to replay, and begin to work my way down the timeframes. Trading like a sniper is not about entries with no drawdown. It is...
Pfizer Inc. (PFE) has announced a new multi-year plan to reduce operational costs by approximately 1.5 billion USD by the end of 2027. This initiative is in addition to a previously announced 4 billion USD cost reduction strategy in response to decreased investments and a sharp decline in sales from its COVID-19 vaccine. Amid these challenges, Pfizer has...
Pfizer ( NYSE:PFE ) has won $107.5 million in damages from AstraZeneca in a US cancer drug patent trial. A Delaware federal jury found that AstraZeneca's lung cancer drug Tagrisso violated its Wyeth unit's patent rights. The jury agreed that AstraZeneca's drug infringed two patents covering methods for treating cancer with the breast-cancer drug Nerlynx, which is...
BMY is here on the daily chart. The double top and death cross of the EMA moving averages makes for a strong candidate to short with shares or take put options. A comparsion of the most recent earnings report with the previous one sixty days earlier tells most of the story. The dual time frame RSI indicator shows ongoing wekaness. I will short BMY here and...
Reasons for bullish bias: - The price has broken the downtrend trendline - An entry at the lower highs (LH) breakout will provide further confirmation - Currently, the price is in a consolidation phase Here are the recommended trading levels: Entry Level(Buy stop): 30.18 Stop Loss Level: 25.26 Take Profit Level 1: 35.1 Take Profit Level 2: 40.02 Take Profit Level 3: Open
Reasons for bullish bias: - Entry at accumulation phase breakout - Bullish Harmonic XABCD pattern on weekly - Strong weekly Bullish divergence - Price broke strong downtrend trendline - Strong bullish weekly candles at support - Positive Earnings Here are the recommended trading levels: Entry Level(CMP): 28.91 Stop Loss Level: 24.65 Take Profit Level 1:...
We're in this from a bit higher. Still holding. We think it's bottoming here. TP 46% from our entry. ~ 56% from here. Would love to swing a weekly SFP today for confirmation, but not really necessary. LTF looks good.
Pfizer Inc. ( NYSE:PFE ) sent shockwaves through the market with a stunning first-quarter performance, catapulting its stock price upward following a robust quarterly beat that surpassed analysts' expectations by a wide margin. The pharmaceutical giant reported adjusted earnings of 82 cents per share, significantly outpacing the forecasted 51 cents per share, and...
In a landmark decision, the Food and Drug Administration (FDA) has given its stamp of approval to Pfizer's groundbreaking gene therapy for hemophilia B, marking a pivotal moment in the field of genetic medicine. Hemophilia B, a rare inherited bleeding disorder affecting thousands in the U.S., has long posed significant challenges for patients and caregivers due to...